Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Follicular 2Head and Neck Neoplasms 2Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1

Interventions

Cisplatin 75Cetuximab 63Radiotherapy 38pembrolizumab 29Radiotherapy, Intensity-Modulated 28Carboplatin 25Fluorouracil 24Docetaxel 24Paclitaxel 19Erlotinib Hydrochloride 13Nivolumab 12Radiation 10Pemetrexed 10durvalumab 8Gemcitabine 8Drug Therapy 8Bevacizumab 7zalutumumab 6Surgical Procedures, Operative 6Panitumumab 6Lapatinib 6Everolimus 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6epacadostat 5Standard of Care 5Oxaliplatin 5Gefitinib 5Afatinib 5Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Head and Neck Neoplasms × duvelisib × Clear all
NCT05057247 2025-10-31

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Dana-Farber Cancer Institute

Phase 2 Completed
26 enrolled 23 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

SecuraBio

Phase 1/2 Terminated
2 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡